Abstract
Introduction
The increasing diagnostic relevance of brain-de-Ž . rived proteins in cerebrospinal fluid CSF led to the w x awareness that their particular dynamics in CSF 1 ) Tel.: q49-551-39-66-19; fax: q49-551-39-20-28.
Ž . E-mail address: hreiber@med.uni-goettingen.de H. Reiber . are different from the dynamics of blood-derived w x proteins 2,3 . So far, there have been no attempts to describe the general dynamics of brain proteins in CSF. With the recognition of the particular relevance of CSF flow rate modulating the concentrations of blood-derived proteins in CSF of patients with a blood-CSF barrier dysfunction, it is of theoretical w x and diagnostic relevance 4-6 to investigate the 0009-8981r01r$ -see front matter q 2001 Elsevier Science B.V. All rights reserved.
Ž . PII: S 0 0 0 9 -8 9 8 1 0 1 0 0 5 7 3 -3 ( )impact of CSF flow rate on CSF concentrations for brain-derived proteins. The relevance of CSF flow was discussed circa 1700 by Fantony and in 1875 by Ž w x. Key and Retzius references in Ref. 7 and achieved scientific relevance by an experimentally founded w x physiology of CSF flow 8 . Current imaging techniques, such as nuclear magnetic resonance spec-Ž w x. troscopy references in Refs. 9,10 , give direct evidence for changing CSF flow rate in neurological w x diseases 9,10 . The CSF velocity rate of children from 1 to 17 years, measured by MRI, are on an Ž w x average higher than the rate values in adults Ref. 9 . and reference therein . These relations correspond to the lower CSF protein concentration in younger age and an increasing protein concentration with decreasing CSF flow rate in older age. The influence of CSF flow rate on protein concentrations in CSF has been described in earlier reports by linear approaches w x 11,12 .
The new theory that combines molecular flux and w x CSF flow rate 2 , shows CSF flow rate as the main modulator of pathological CSF protein concentrations, i.e., reduced CSF flow rate is sufficient to explain quantitatively the empirically measured, non-linear increase of blood-derived CSF protein concentrations in neurological diseases. Potentially, also the view of blood-CSF barrier dysfunction could be changed from the still widespread understanding of a morphological AleakageB-model to a biophysical concept of increased molecular flux with decreasing w x CSF flow rate 2,6 .
Blood-deriÕed proteins in CSF
The main fraction of proteins in the normal cere-Ž . brospinal fluid CSF originates from blood, e.g., albumin which constitutes 35-80% of total protein w x in CSF 6 . In neurological diseases with a blood-CSF barrier dysfunction, all blood-derived protein fractions in CSF are increased. This increased transfer of blood proteins into CSF is characterized by a hyperbolic function between protein concentrations in CSF. The hyperbolic discrimination function for the upper limit of the reference range for blood-derived fractions in CSF is the basis for established CSF serum quotient diagrams, now of widespread w x use in the diagnosis of neurological diseases 4-6,13 .
Brain-deriÕed proteins in CSF
About 20% of the proteins in CSF are predomiw x nantly brain-derived, but rarely brain-specific 14 . The basic feature of predominantly brain-derived proteins is their higher concentration in CSF compared to serum, inducing a net flux out of CSF compared with blood proteins with a net flux into Ž . CSF Table 1 . For some of the predominantly brain-derived proteins, a blood-derived fraction in CSF is not negligible.
Together with the pathological changes of CSF concentrations of blood-derived proteins, a particular modulation of the concentrations of brain-derived Alb ( )w x proteins is observed 1 , depending on the source of the proteins. So far, a theoretical approach for understanding the dynamics of brain proteins has been missing, as has a corresponding evaluation concept for brain proteins to facilitate the diagnosis of neurological diseases. The analysis of brain proteins represents an important extension of the basic CSF analysis program. As an example of the increasing diagnostic relevance, brain proteins help to differentiate between different causes of dementia, like Alzheimer's disease, Creutzfeldt-Jakob disease or w x multiinfarct dementia 15-18 . This paper describes the empirical data for brain proteins with changing CSF flow rate and gives for the first time a theoretically founded, physiologically relevant interpretation of the dynamics of brain proteins in CSF and points to the consequences for clinically relevant data evaluation.
Different sources of brain-deriÕed proteins
Three groups of brain-derived proteins investigated in this study are selected as representatives of Ž . different origins and dynamics in CSF: a proteins originating from neurons and glial cells, like tau protein, S-100 and neuron-specific enolase, which are primarily released into ventricular and cisternal Ž . CSF, b proteins which are primarily released from leptomeninges into CSF, like b-trace protein and Ž . cystatin C and c proteins with a non-negligible blood-derived fraction in CSF, like transthyretin, Ž . angiotensin converting enzyme ACE or the soluble Ž . intercellular adhesion molecule s-ICAM as a third group.
Ž . Neuron-specific enolase NSE , the gamma, gamma dimer with a molecular weight of 78 kDa originates predominantly from neurons and neuroendocrine cells. The large amount found in the brain means that NSE is a very sensitive marker for fast neuronal degradation. It can be detected either in w x w x CSF 19,20 , e.g., in Creutzfeldt-Jakob disease 17 , w x or, in blood 21 for the prognosis of clinical outcomes after cerebral hypoxia, brain infarction or headrbrain trauma.
S-100 protein is an acidic, calcium-binding protein found in the brain as homodimer or heterodimer with a molecular weight of 21 kDa. S-100B, the beta, beta dimer, is present in high concentrations in Cystatin C, the former gamma trace protein, is a cysteine proteinase inhibitor with a molecular weight of 13.3 kDa. It is produced by all nucleated cells, including neuroendocrine cells and cortical neurons w x 27 . A higher concentration of cystatin C in CSF than in serum allows cystatin C to be classified as a predominantly brain-derived protein in CSF with a Ž . negligible blood-derived fraction -1% . Besides a dominant release from the choroid plexus compared w x to the residual brain 28 , a release of cystatin C from w x leptomeningeal cells in vitro has been reported 29 .
Transthyretin, the former prealbumin, functions as a carrier protein for thyroxine and for vitamin A by one-to-one association with retinol binding protein w x 30 . Transthyretin in CSF originates predominantly from the choroid plexus as the only source of synthew x sis in brain cells 31 . In contrast to NSE, S-100B, tau protein and b-trace protein, the blood-derived concentration of transthyretin is not negligible. With an 18-fold higher concentration of liver-derived transthyretin in blood compared to CSF, a small blood-derived fraction of about 10% can be calcu- Angiotensin converting enzyme has restricted clinical relevance for diagnosis of neurosarcoidosis. Its CSF concentration is primarily blood-derived, and particular care is needed to detect its increased brain-derived fraction in case of blood-CSF barrier w x dysfunctions 1 .
Material and methods

w x
The methods for analysis of b-trace protein 26 , w x w x w x transthyretin 1 , S-100 18 , NSE 17,21 , tau protein w x w x w x 16 , s-ICAM 33 and ACE 1 are performed as reported in the references. Only for tau protein in Ž serum the enzyme immunoassay Innogenetics, The . Netherlands was modified for higher sensitivity by increasing the sample volume threefold and reducing the reagent volume to 1r3 with the threefold concentration of its constituents. Cystatin C is analysed with Ž a particle amplified nephelometric assay Dade . Behring, Marburg, Germany . Albumin, IgG, IgA and IgM are analysed by immunochemical nephw x elometry 4 .
Ž . Intrathecal fractions IF , as shown in Fig. 1 . kDa , such a value could be used to calculate the theoretical blood-derived fraction in the dominantly brain-derived CSF concentration. With the known mean serum concentration value and the calculated gradient, a mean blood-derived CSF concentration can be calculated and expressed as % of the measured total CSF concentration. Calculations of blood-derived fractions in CSF have been reported w x w x w x for transthyretin 1 , s-ICAM 33 and for ACE 1 .
Patients
Lumbar CSF and serum samples originate from patients of the Department of Neurology, University Gottingen. All samples were taken for routine analysis with the informed consent of the patients. The presented data in the study are partly reevaluated from earlier publications of the Neurochemistry Laboratory in Gottingen.
In particular, this refers to Albumin, IgG, IgA and w x w x IgM 2 for Figs The already published data as well as the new data in this article are based on the following diagnostic criteria.
Ž .
1 Normal control patients have been defined Ž clinically absence of brain-organic diseases accord-. ing to clinical and imaging criteria and via their Ž CSF and blood data normal CSF leucocyte count and protein values, and normal blood leucocytes and Ž . . plasma C-reactive protein CRP values . Single subgroups of patients, e.g., with tension headache or non-inflammatory polyneuropathies, as far as they have been found to be indistinguishable in mean and range of concentration values from the normal reference range, have been combined for statistical evaluation.
2 Non-inflammatory diseases with blood-CSF barrier dysfunction: This group contained patients with increased albumin CSFrserum quotients due to 
Ž .
IgG Alb spinal canal stenosis, a spinal tumour or disc prolapse. They showed increased CSF total protein and albumin quotients, normal cell counts as well as typical findings in electromyography and magnetic resonance tomography of the spine. Oligoclonal IgG in CSF was an exclusion criteria.
Ventricular CSF
Ventricular CSF samples originated from patients of the Neurosurgery Department of the University of Gottingen, routinely analysed to exclude a postsurgery inflammation. The samples have been extracted from a drainage. ( )The group of AnormalB ventricular CSF samples is recruited from a larger collection of samples with low albumin quotient, absence of haemoglobin or blood contamination as well as absence of oligoclonal IgG. The cell count was -5rml.
The group with increased ventricular albumin quotients was recruited from patient with a CSF flow restricting stenosis or tumour. For some parameters, Ž the early bacterial infection before onset of the . humoral immune response could be included.
Results
CSF to serum gradient of brain-deriÕed proteins
The concentrations of predominantly brain-derived proteins in normal lumbar CSF together with the corresponding serum concentrations are shown in 
Ventricular to lumbar CSF concentration gradient
The concentration gradient between ventricular and lumbar CSF, as a second feature of brain-derived proteins, is shown in Table 2 . Proteins released from Ž . brain cells NSE, S-100B and tau protein have the highest concentration in ventricular CSF decreasing along its flow path through the subarachnoid space. Vice versa, proteins released from leptomeninges into CSF are increasing in concentration along the Ž . subarachnoid space up to 11-fold beta trace protein .
The gradient for transthyretin refers to the choroid plexus derived fraction in CSF calculated from total transthyretin in CSF by subtraction of the blood-de-Ž . rived fraction Section 2 . The concentration of total transthyretin is decreasing slightly between ventricular and lumbar CSF, in spite of the small but steady net flux of blood-derived molecules into CSF, as consequence of the overall bloodrCSF gradient shown in Table 1 . These data are consistent with an w x earlier report 32 .
Brain proteins and CSF flow rate
A third feature of brain-derived proteins in CSF is their dynamics due to changing CSF flow rate in cases of neurological diseases with Ablood -CSF barrier dysfunctionB. With pathologically decreasing CSF flow rate, i.e., increasing Q in Fig. 3a-f , we Alb find again differences between the first group of brain cell-derived proteins with constant concentrations, which show an invariance for changes of CSF flow rate, and the second group of leptomeningeal cell-derived proteins, which show a linearly increas-Ž ing concentration. Data for the first group tau pro-. tein, S-100B and NSE , and for the second group . w x molecule s-ICAM, Fig. 3f as well as ACE 1 represent a third group. The data for the source-related differences in the dynamics can be summarized for each protein.
( ) 3.3.1. Neuron-specific enolase NSE
With a CSFrserum concentration ratio of 1:1 Ž . Ž . Table 1 , the intrathecal brain-derived fraction of Ž NSE in CSF can be calculated to be still ) 99% the blood-derived fraction is smaller than 1% due to an interpolated molecular size-dependent CSFrblood gradient of about 1:200 for a theoretical, solely . blood-derived fraction . The concentration decreases Ž . between ventricular and lumbar CSF 2:1, Table 2 . The mean NSE concentration in lumbar CSF does not change with increasing Q in case of a bloodAlb CSF barrier dysfunction as shown in Fig. 3a, i.e., is invariant to reduced CSF flow rate. Table 1 shows that the brain-derived fraction in Ž . CSF for S-100B protein beta, beta dimer exceeds 99% due to an empirical CSFrserum ratio of 18:1 and a theoretical molecular size-dependent blood-de-Ž . rived fraction -1:50 Section 2 . Between ventricular CSF and lumbar CSF, the S-100 concentration Ž . decreases 3.5:1, Table 2 . Fig. 3b shows the mean S-100 concentration which is invariant to increasing Q . Alb 
S-100 protein
Tau protein
The CSF data in this paper refer to total tau protein including PHF-tau, the hyperphosphorylated form of tau protein. The lumbar CSF concentration Ž . exceeds 10-fold the blood concentration Table 1 and tau protein concentration decreases between ven-Ž . tricular and lumbar CSF Table 2 . In cases of non-inflammatory CSF flow reduction, there is no increase of tau protein concentration in CSF with Ž . increasing Q Fig. 3c . The reported lower values Alb of CSF-tau protein in some inflammatory processes w x 16 are confirmed in Fig. 3c for cases of neuroborreliosis. The mean of decreased values was about 50% of normal lumbar CSF but again was independent of Q , i.e., invariant to changing CSF flow rate. . lumbar canal stenosis , the b-trace protein concentra-Ž . tion increases linearly Fig. 3d . A very particular influence, reducing lumbar CSF b-trace protein concentrations to about 60% of normal, is observed in w x Ž . bacterial or tuberculous meningitis 36 Fig. 3d , but Ž . not in viral infections e.g., HSV encephalitis of the central nervous system. Amazingly, in this particular type of pathological processes the b-trace protein CSF concentrations in lumbar CSF are also independent of Q , like NSE, S-100, or tau protein concenAlb trations usually are.
Cystatin C
Cystatin C, also known as gamma-trace protein, has a fivefold higher concentration in CSF than in Ž . serum Table 1 , which allows us to speak of cystatin C as a brain-derived protein in CSF with a negligible Ž . blood-derived fraction -1% . As shown in Table 2 , the concentration is increasing 3.5-fold between ventricular and lumbar CSF due to its leptomeningeal release. This normal rostro-caudal gradient is less Ž . steep 30% than for b-trace protein. The effect of a pathological decrease of CSF flow rate is of similar magnitude for the pathological increase of lumbar cystatin C concentration. Again, the slope for cystatin C is about 20% of that observed for b-trace protein. Another similarity in the dynamics of both these proteins is seen in cases of bacterial meningitis, where the pathological meningeal reaction leads to a decreased lumbar concentration of cystatin C like b-trace protein with about 60% of normal values and also with an invariance of the cystatin C concentra-Ž . tion with decreasing CSF flow rate data not shown .
Transthyretin
In contrast to NSE, S-100B, tau protein or b-trace protein for transthyretin, the blood-derived concentration is not negligible. With an 18-fold larger concentration of liver-derived transthyretin in blood Ž . compared to CSF Table 1 , a small blood-derived fraction of about 10% can be calculated to contribute to transthyretin concentration in normal lumbar CSF Ž . w x 3% in ventricular CSF 1 . Transthyretin data for ventricular, cisternal or lumbar CSF have been re-( )w x ported earlier 32 , indicating that there is a small decrease of concentration between ventricular and lumbar CSF and an increase of transthyretin concentrations with reduced CSF turnover below a spinal Ž . blockade typically a restricted CSF flow rate . The data in Table 2 confirm this decrease between ventricular and lumbar CSF for the choroid plexus-de-Ž . rived calculated CSF fraction. The blood-derived Ž fraction in CSF increases with increasing Q Fig. Alb . 3e . Using a mathematical correction for the bloodw x derived fraction 1 , it becomes visible that the plexus-derived fraction is independent of changing Q , like the concentration of the brain proteins Alb S-100, NSE or tau protein.
Biophysics of brain proteins in CSF
The ventricular CSF concentration of a brain-derived protein depends on its tissue concentration, the molecular size-dependent diffusion into CSF and the Ž . Ž . a The decrease of concentrations between ventricular and lumbar CSF for brain-derived proteins depends on the different tissue concentrations around CSF space and the corresponding local gradients.
Tau protein, NSE or S-100B, due to their neuronal or glial source must have higher concentrations in the tissue around the ventricular and cisternal CSF space than around the lumbar space in leptomeninges. The outsiderin gradient D c in the range of ventricles is inverted to an insiderout gradient in Ž lumbar CSF where the concentration in CSF flow-. ing down from ventricles is larger than in the Ž . surrounding tissue leptomeninges , with only a small local release of neuronal or glial proteins. This is different for the leptomeningeal proteins. The b-trace protein concentration is much higher in the leptomeninges than in the periventricular tissue, i.e., there is no inversion of the gradient D c downstream. These conditions are sufficient to explain the observed decreasing rostro-caudal concentration gradi-Ž ent of the tau protein group 3.5:1 to 1.5:1 in Table  . 2 and the increasing gradient for the b-trace protein Ž . group 1:11 to 1:3.5 in Table 2 .
Ž . b In case of a pathological decrease in CSF Ž . Ž . volume DVol turnover rate DVolrDt and an independently steady release of brain cell-derived proteins via extracellular space into CSF, we get an increase of their concentrations c in CSF and subsequently a decrease of the gradient D crD x. With a decreasing D c, the molecular flux, J , is subsein quently reduced, counteracting to some extent the Ž . effect of reduced CSF flow rate increasing c . This effect can be regarded as a physical negative feedback loop, analogous to the metabolic inhibitory feedback loops in many biochemical processes. But nevertheless, with decreasing CSF turnover rate, the local concentration in CSF can still be increasing as long as a gradient D c ) 0.
In the tau protein group, the constant concentration in lumbar CSF, invariant to decreasing CSF Ž . flow rate Fig. 3a-c , is a consequence of the quantitatively compensating effect of increasing concentra-Ž . tion c in ventricular CSF and the subsequently increasing molecular outflux, J , along the subout arachnoid space, in particular in the spinal canal, due to an increase of the local insiderout gradient In contrast, the leptomeningeal proteins show an increasing lumbar CSF concentration with decreas-Ž . ing CSF flow rate due to a non-inflammatory cause Ž . Fig. 3d . This can easily be explained by the steady release of b-trace protein into CSF according to the local outsiderin gradients along the whole way downstream, which, together with the reduced volume turnover, must account for its increased CSF concentration.
The relative increase of CSF concentrations for b-trace protein with decreasing CSF flow rate is smaller in lumbar than in ventricular CSF as shown by the mean functions of the regression lines. In Fig.  3d , the linear regression line has the function:
Alb
The corresponding function for the ventricular CSF is: Ž .
The data of ventricular CSF are from a group of Ž . patients n s 13 without inflammatory processes but Ž a blood-CSF barrier dysfunction data not shown . Ž . here . The intercept at Q s 0 in Eq. 3 is obtained Alb from the empirical regression line and should be somewhat above zero. The corresponding mean con-Ž . centration of normal V-CSF n s 7 is 1.5 mgrl Ž .
y3 Table 2 
Discussion
CSF proteins from brain cells
Proteins in CSF which originate from brain cells, like neurons or glial cells, which enter CSF primarily in the ventricular and cisternal spaces show the same dynamic:
Ø their concentration is decreasing between normal ventricular and lumbar CSF and Ø their concentration does not vary with pathologically decreasing CSF flow rate, i.e., in cases of a so-called blood-CSF barrier dysfunction for blood-derived proteins.
The first observation, the decreasing rostro-caudal gradient, is easily explained by a net diffusion of neuronal and glial proteins from insiderout of CSF on the way downstream. This is due to the inversion In this way, the observed empirical data for NSE, S-100, tau protein or choroid plexus-derived transthyretin fraction are sufficiently explained by the theoretical model in which CSF flow rate represents the main modulator of CSF protein concentrations.
CSF proteins from meningeal cells
Proteins like b-trace protein or cystatin C, which originate primarily from leptomeningeal cells, show:
Ø An increasing concentration between normal ventricular and lumbar CSF. Ø A linearly increasing concentration in CSF in case of pathologically decreasing CSF flow rate. Ø A particular modification is observed in inflammatory meningeal processes.
The rostro-caudal increase of b-trace protein and Ž . cystatin C concentrations Table 2 under normal conditions are easily understood as a steady release of proteins into CSF along its flow path, due to a local outsiderin concentration gradient at the border with the subarachnoid space. The b-trace protein concentration is increasing from 1.5 mgrl in the ventricles to 16.6 mgrl in the lumbar subarachnoid space. This larger concentration in lumbar CSF has consequences for the dynamics of b-trace protein in the case of a pathologically reduced CSF flow rate.
Ž . Ž . In Eqs. 2 and 3 , the smaller slope for lumbar CSF Ž . indicates that the local gradient D crD x between tissue and CSF space is larger in the ventricles than in the lumbar subarachnoid space. The 11-fold increase of b-trace protein concentration between ventricular and lumbar CSF is not related to a correspondingly 11-fold higher release of b-trace protein in the leptomeninges compared to the extra-ventricular tissue.
This second observation, the linear increase of b-trace protein concentration in lumbar CSF in case of pathologically decreasing CSF flow rate, can be important also from a theoretical point of view. This linear increase, e.g., of b-trace protein or cystatin C concentration, is different from the non-linear hyperw x bolic function 2 for blood-derived proteins in CSF Ž . Fig. 2 .
Ž . The type of positive physical feed back loop for blood-derived proteins is missing in the case of the Ž cell metabolism-dependent release of proteins b-. trace protein, cystatin C, etc. into CSF; i.e., an increasing CSF concentration of leptomeningeal proteins in CSF does not induce an increased release of these proteins from brain cells. Such a process of spontaneous induction and increased expression of Ž . proteins analogous to an autocatalytic process has not been observed so far. This explains why the dynamic of these proteins can be described by Fick's first law with a linear relation between molecular flux and concentration gradient. As an interesting support of the relevance of CSF flow for brain-dew x rived proteins, the report of Grubb and Lofberg 27 shows for cystatin C an age-related CSF concentraw x tion, decreasing shortly after birth 27 . This is consistent with the age-related increase of CSF flow rate w x 2,6 due to the maturation of arachnoid villi at the time of birth and shortly after: A maximum CSF flow rate is reached about 4 months after birth with the correspondingly lowest CSF protein concentration, slowly increasing again over the next decades w x due to a decreasing CSF production rate 12,37 . This similarity of the normal age-related dynamics Ž . between meningeal proteins linear increase and ( )Ž . blood-derived proteins hyperbolic increase gives further evidence for the relevance of CSF flow rate.
These findings from pathology confirm that the molecular fluxrCSF flow theory represents a complete conceptual framework for explaining the dynamics of both the blood-and brain-derived proteins in CSF. To support the validity of the theory, we point to its interpretative power in making sense of unusual observations. This is shown in three examples below.
Ž . 1 A particular example is represented by the dynamic of b-trace protein in the case of bacterial or tuberculous meningitis. In these cases, b-trace protein values in lumbar CSF are below normal concentrations but remain constant, i.e., independent of the w x Ž . decreasing CSF flow rate 36 Fig. 3d . The observed data could be explained as a reduced release of b-trace protein along the lumbar meningeal region in the case of bacterial meningitis. In fact, the CSF concentrations, lower than normal lumbar CSF concentrations, represent the lower concentrations typical for cisternal CSF. With the knowledge that in bacterial meningitis the meningeal release of b-trace protein is inhibited, the measured protein concentration in lumbar CSF would originate primarily from tissue around the ventricular and cisternal area, like NSE, S-100 or tau protein. In this sense, the b-trace protein concentration in these inflammatory meningeal processes follows the rules for the brain cell-derived proteins with an invariance to changes of CSF Ž . flow rate Fig. 3d in contrast to the non-inflamma-Ž . tory reduction of CSF flow rate Fig. 3d . These Ž . aspects of b-trace protein and cystatin C raise new questions for the investigation of leptomeningeal processes in a bacterial meningitis, a disease which still has the highest fatal outcome amongst inflammatory neurological diseases.
2 The normal CSF concentration of the soluble cell adhesion molecule, s-ICAM, originates with w x more than 70% from blood 33 and the s-ICAM CSFrserum quotient should follow a hyperbolic function with increasing albumin quotient as shown Ž . for other blood-derived proteins Fig. 2 . In fact, the quotient, Q , approaches a limiting value like a ICAM Ž . saturation curve Fig. 3f . From molecular fluxrCSF flow theory, we understand that there must be, in addition to diffusion, an influence involved in the pathomechanism, which is counteracting a steady increase of concentration. Such a type of reaction is observed in negatiÕe feed back loops, common to many biochemical regulation processes. So in this case, we must propose either a faster s-ICAM degradation or an elimination process with increasing s-ICAM concentration. This is typical for biochemically controlled substances, a condition which has been shown to be fulfilled for upregulation of sw x ICAM biosynthesis, too 34 . This leads to the understanding that s-ICAM is not inert to biochemical reactions and further specific investigations regarding s-ICAM control mechanisms are needed. This result is very different from the approach proposed on the basis of an earlier, unfounded barrier model w x 38 , which conflicts with established observations on blood-CSF barrier dysfunction.
3 Evaluation of transthyretin in CSF, about 90% of which originates from the choroid plexus, represents another intelligible application of the molecular w x fluxrCSF flow theory. As shown earlier 1 by a mathematical approach, it is possible to subtract the calculated blood-derived fraction of transthyretin from the total concentration in CSF. In this way, we can demonstrate that the choroid plexus-derived fraction behaves like NSE, or S-100, or tau protein: it Ž . remains independent of CSF flow rate Fig. 3e .
So, finally we get a consistent concept for the evaluation of brain-derived and blood-derived proteins or proteins with mixed sources in the brain, leptomeninges or blood. This concept shows that it is important for evaluation of some brain proteins in CSF to refer to the albumin quotient as a measure of CSF flow rate. The lack of a Q -related evaluation . 3d may lead to erroneous interpretations of an in-Ž . creased or decreased protein concentration in lumbar CSF. In initial investigations to introduce a new brain protein into diagnostic approaches, the detection of the ventricular to lumbar concentration gradient in addition to the CSFrblood gradient can give important information about the source of a protein and its pathophysiological processes. This basic information helps also to decide whether the absolute Ž concentration Fig. 3a-d , cases of dominantly brain-. derived proteins or the CSFrserum concentration Ž quotient Fig. 3e and f, cases of dominantly blood-. derived proteins should be used to produce the most sensitive evaluation. This evaluation concept for brain ( ) proteins completes the evaluation programs for intrathecal synthesis of blood-derived proteins in w x CSFrserum quotient diagrams 4-6 .
It seems beyond any doubt that CSF turnover is the crucial determinant for the concentration of its macromolecular components. The empirical data and their interpretations for clinical purposes refer to a mean turnover rate, which does not need to take into account the local and temporal fluctuations, including to-and-fro motions of the CSF by cardiac cycles w x Ž 9,10,40,41 or the circadian rhythms references in w x. Ref. 9 . The usually reported aqueductal CSF velocities can be very fast due to an aqueduct stenosis w x 9 . But, the absolute values of aqueductal velocities cannot be regarded as representative for the overall CSF turnover rate. This is a limitation of imaging techniques for a correlation with the disease-related change of the albumin quotient. 
